Please login to the form below

Not currently logged in
Email:
Password:

RSV

This page shows the latest RSV news and features for those working in and with pharma, biotech and healthcare.

Merck says it has plenty in the pipe beyond Keytruda

Merck says it has plenty in the pipe beyond Keytruda

The investors’ meeting covered the highlights of the company’s pipeline outside cancer as well, including next-generation pneumococcal vaccines and candidates for respiratory syncytial virus (RSV), cytomegalovirus (CMV) and dengue

Latest news

More from news
Approximately 2 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    The previous licensing deal was for exclusive global rights to the phase 1‐ready RSV compound, AK0529 which is now in a phase 2 study.

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    Company acquisition. Anti-viral therapies, lead compound AL-8176 an oral antiviral in phase II for infant RSV.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Alios has an oral anti-viral in phase 2 for treatment of infant respiratory syncytial virus (RSV) which complements J&J's early stage programmes in RSV.

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    175. MicroDose Therapeutx / Teva. Acquisition. Acquisition of inhalation technology including MDT-637 for RSV (phase II).

  • Pharma deals during June 2013 Pharma deals during June 2013

    The deal brings to Teva a multi dose dry powder nebuliser technology and MDT-637, a low dose, small molecule, fusion inhibitor for the treatment of respiratory syncytial virus (RSV).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Dutch biotech Mucosis promotes Thomas Johnston to CEO Dutch biotech Mucosis promotes Thomas Johnston to CEO

    development and commercialisation of the Mimopath platform including our RSV vaccine candidate.". ... During the last 12 months Mucosis has completed a clinical proof of concept study in human influenza for Mimopath and advanced respiratory syncytial

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics